Literature DB >> 2294365

Improved survival after heart-lung transplantation.

P M McCarthy1, V A Starnes, J Theodore, E B Stinson, P E Oyer, N E Shumway.   

Abstract

Sixty-two patients underwent 65 heart-lung transplant operations before April 1989. Thirty of these patients (operated on March 1981 to February 1986) were given cyclosporine and prednisone for immunosuppression. These 30 patients (group 1) are compared with the 32 most recent patients (group 2) treated with cyclosporine, prednisone, and azathioprine. Patient characteristics (group 1 versus group 2) were similar including age (mean 32 versus 26 years) and indication for operation (51% versus 38%, primary pulmonary hypertension; 46% versus 45%, Eisenmenger complex; 3% versus 17%, other). The perioperative (in-hospital) mortality rate was 35% in group 1 versus 16% in group 2. Obliterative bronchiolitis developed in 12 (63%) of 19 hospital survivors in group 1 from 2 months to 49 months postoperatively (mean 12 months). This complication has developed in five (20%) of the 25 hospital survivors in group 2 from 3 to 13 months postoperatively (mean 8 months). Overall, 24 of the 30 patients in group 1 died (infection in eight, obliterative bronchiolitis in five, graft coronary artery disease in two, other causes in nine). Eight of the 32 patients in group 2 died (infection in six, other cases in two). Survival rates for group 1 patients were 60% at 1 year, 50% at 2 years, 43% at 3 years, and 25% at 5 years. Survival rates for group 2 patients were 73% at 1 year, 73% at 2 years, and 65% at 3 years (p less than 0.05). When group 2 patients were compared with 134 patients undergoing heart transplantation during the same time period, there was no difference in survival. Routine bronchoscopic surveillance in the more recent group of patients has led to the earlier detection of rejection and infection. In combination with decreased perioperative mortality and augmented immunosuppression, this had led to improved survival in our more recent heart-lung transplant recipients. In addition, the earlier recognition of infection and rejection has led to a decrease in severity of obliterative bronchiolitis.

Entities:  

Mesh:

Year:  1990        PMID: 2294365

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Single lung transplantation and pulmonary hypertension.

Authors:  T Higenbottam
Journal:  Br Heart J       Date:  1992-02

2.  The treatment of primary pulmonary hypertension.

Authors:  N G Uren; C M Oakley
Journal:  Br Heart J       Date:  1991-08

Review 3.  Lung transplantation.

Authors:  L T Tanoue
Journal:  Lung       Date:  1992       Impact factor: 2.584

4.  Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension.

Authors:  T W Higenbottam; D Spiegelhalter; J P Scott; V Fuster; A T Dinh-Xuan; N Caine; J Wallwork
Journal:  Br Heart J       Date:  1993-10

Review 5.  Heart-lung and lung transplantation for cystic fibrosis.

Authors:  N Lewiston; V Starnes; J Theodore
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

6.  Medium term results of lung transplantation for end stage pulmonary sarcoidosis.

Authors:  S Walker; G Mikhail; N Banner; J Partridge; A Khaghani; M Burke; M Yacoub
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.